Disease-Modifying Digital Therapeutics for Neurodegenerative Diseases

Cognito is a clinical-stage company developing novel digital therapeutics with a proprietary neuromodulation platform which holds the promise for disease-modification in neurodegenerative diseases such as Alzheimer’s.

The Science

Groundbreaking science is our core

Cognito founders Li-Huei Tsai, PhD, and Ed Boyden, PhD, pioneers in brain research, published a landmark study showing dramatic benefit in treating Alzheimer’s using a non-invasive brain stimulation technique. These compelling results are the foundation of the clinical trials we are conducting today.

Knowing that in Alzheimer’s Disease there is a deficiency in certain brainwave frequencies, our founders discovered that stimulating the brain at a specific frequency had the effect of reactivating the immune system in the brain. This effect correlated with a reduction in amyloid plaques and tau tangles, typical hallmarks of the disease.

Read our scientific publications here
Our Approach

A breakthrough advancement in neuromodulation

Cognito was founded in 2016 based on experiments conducted by scientific founders Li-Huei Tsai and Ed Boyden at MIT. These initial experiments led to the development of our proprietary neuromodulation platform and the completion of multiple clinical studies in Alzheimer’s disease.

Our approach is a non-invasive neurostimulation that induces gamma oscillations in the brain and was designed to accommodate the specific needs of individuals with Alzheimer’s disease. Since our founding in 2016, we have completed more than 35,000 treatment sessions in multiple clinical studies to determine the effects of this novel therapy on Alzheimer’s disease.

In December 2020, we received FDA Breakthrough Device Designation and will enroll in a pivotal study before the end of 2021.

  • 2021

    • Planned enrollment in pivotal study for Alzheimer’s disease

    • Main study completion of ETUDE

    • 35,000 treatment sessions

  • 2020

    • FDA Breakthrough Device designation

    • Main study completion of OVERTURE

    • 25,000 treatment sessions

  • 2019

    • Main study completion of FLICKER

  • 2018

    • Launch of three clinical studies (ETUDE, OVERTURE, FLICKER)

    • 15,000 treatment sessions

  • 2017

    • Completion of safety and feasibility studies

  • 2016

    • Completed development of product platform

    • Cognito founding

  • Pre-2016

    • Initial MIT experiments conducted

Our Pipeline

A broad portfolio of targets ready to move into clinical studies

Given the applicability of our mechanism of action to multiple neurodegenerative disorders, we have developed a broad portfolio of pipeline opportunities. Our non-invasive approach speeds development time and allows for rapid execution of early feasibility studies.


Therapy Development Stage
Therapeutic Application

Discovery

Preclinical/
Translational

Early Clinical

Pivotal Clinical

Approved

Alzheimer’s Disease

Disease modifying therapy

Alzheimer’s Rare Disease

Genetic variants

Down syndrome
Ischemic Stroke
TBI / CTE
Concomitant therapies
CTX-006
CTX-007
CTX-008
CTX-009

Get in touch with our team to learn more about indication opportunities: info@cognitotx.com

Careers

Join the Team

We are a team of inspired and inquisitive scientists, engineers, and designers. We have a passion for helping others and are clever problem-solvers who value interdisciplinary collaboration and diverse perspectives. We are looking for exceptional individuals who share the ideals of our growing team and our passion for developing life-changing therapies. Cognito has locations in Boston and the San Francisco Bay Area.


View Openings


Contact

Get in Touch